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Background: There is increasing recognition of association of nonalcoholic fatty liver dis-
ease (NAFLD) with cardiovascular disease (CVD). Metabolic syndrome is common in both
NAFLD and cardiovascular diseases. Our study is designed to investigate the association of
NAFLD with cardiovascular disease.
Methods: It's a cross-sectional study which included 104 patients of coronary artery disease
and hypertensive heart disease. Those patients having secondary causes of steatosis were
excluded. Complete cardiovascular evaluation which included assessment of metabolic
syndrome, routine biochemistries, viral markers, Ultrasonography (USG) abdomen, hs-CRP
and TNF-a levels were obtained for all patients.
Results: Of all patients with cardiovascular disease, 19.2% (20/104) had essential hyper-
tension with hypertensive heart disease the remaining 80.8% (84/104) patients had
ischemic heart disease (IHD). On USG 69.2% (72/104) had NAFLD, these 50% (36/72) had
grade 1 NAFLD and the rest grade 2 NAFLD. The hs-CRP levels and TNF-a were significantly
higher in patients with NAFLD (p-value <0.001) and within patients with NAFLD the levels
were higher in patients with grade 2 NAFLD. Also, binary logistic regression showed that
high body-mass index (BMI), raised serum triglyceride levels, increased waist circumfer-
ence and hypertension were significantly associated with the presence of NAFLD.8.
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i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 5 7 4e5 7 9 575Conclusion: Our data indicates that NALD is highly prevalent in patients of cardiovascular
disease (69.2%) and is significantly associated with metabolic syndrome and its individual
components. The levels of hs-CRP and TNF-a were significantly higher in patients with
NAFLD and showed an increasing trend with the severity of fatty liver.
Copyright © 2014, Cardiological Society of India. All rights reserved.1. Background
Nonalcoholic fatty liver disease (NAFLD) encompasses a
spectrum of clinic-pathologic entities that have in common
the presence of fat accumulation in the liver in the absence of
significant alcohol consumption. NAFLD is increasingly diag-
nosed worldwide and considered to be the commonest liver
disorder in Western countries,1,2 affecting approximately
15e30% of the general population, and its prevalence in-
creases steadily to 70e90% in people with obesity or type 2
diabetes.3,4 The common occurrence of NAFLD in the
AsiaePacific region is partially attributable to the increasing
prevalence of the major risk factors for NAFLD like the
metabolic syndrome and its individual components.5,6 Esti-
mates of its current prevalence range from 5% to 30%,
depending on the population studied.7e9
NAFLD is strongly associated with the major components
of the metabolic syndrome. Increasing recognition of the
importance of NAFLD and its strong relationship with the
metabolic syndrome has stimulated an interest in the possible
role of NAFLD in the development of cardiovascular disease
(CVD). Recent studies have pointed out the association be-
tween NAFLD and high cardiovascular risk. The survival of
NAFLD patients has been shown to be lower than expected
compared to the general population. Mortality is even higher
amongst individuals with nonalcoholic steatohepatitis
(NASH), and this mortality was primarily cardiovascular,
rather than liver related.10 This suggests that NAFLDmight be
actively involved in the pathogenesis of CVD rather than just
being a silent marker of CVD.11
Liver is the center for the production of classical bio-
markers of inflammation and endothelial dysfunction. Their
secretion is partly dependent on factors that are up-regulated
in the presence of insulin resistance and the metabolic syn-
drome. IL-6 and TNF-a are the major stimuli responsible for
increased hepatic production of C-reactive protein (CRP),
fibrinogen and other acute-phase proteins.12,13 It has been
shown that fibrinogen and CRP levels, which are known CVD
risk factors, are increased in NAFLD patients, particularly in
those with NASH.14 Tumor necrosis factor-a (TNF-a) has been
associated with NAFLD,15,16 moreover, this inflammatory
pathway is also shared by cardiovascular disease.17e19
Though the current evidence indicates a strong, graded
relationship between the histological severity of NAFLD and
atherosclerosis, the key questions remain whether NAFLD
plays a direct role in CVD pathogenesis or whether an
inflamed liver (NASH) adds to the CVD risk above the effect of
steatosis alone. The biological link may be the shared meta-
bolic and prothrombotic inflammatory factors and thecommon molecular events playing a role in the pathogenesis
of NAFLD and CVD. Recently, NAFLD/NASH per se has been
shown to exacerbate CVD risk, independently of shared
metabolic risk factors, through the release of pro-atherogenic
factors.20
In India, both NAFLD and cardiovascular disease appear to
be on a rising trend. However, the literature about the preva-
lence of NAFLD in patients with CVD is deficient. And with the
evolution of the metabolic syndrome pandemic the preva-
lence of NAFLD have increased in the developed countries.21
Similar trends are expected in India we therefore planned to
study prevalence and correlation of NAFLD in Indian adults
with established cardiovascular disease.2. Methods
For the current study 104 consecutive patients of both sex and
age of 18 years having cardiovascular disease, who fulfilled
the inclusion and exclusion criteria and gave informed con-
sent, were enrolled from the outpatient department of J.N.
Medical College, Aligarh between August 2010 and June 2011.
The aim of the studywas to estimate the prevalence of NAFLD
in patients with coronary artery disease and/or hypertensive
heart disease and to assess its association with metabolic
syndrome and/or elevated hs-CRP or TNF-alpha. Diagnosis of
coronary artery disease was based on history of angina pec-
toris with ECG abnormalities as per Minnesota code22 or the
Whitehall criteria as applied in theWHO'sMultinational Study
of Diabetes and Vascular Disease,23 myocardial infarction
and/or subjects with confirmed CAD on angiography. Exclu-
sion criteria were patients having known other liver diseases
including presence of hepatitis B or C infection, biliary
obstruction, chronic alcohol consumption (ethanol ingestion
>20 g/day), Wilson's disease, drugs reported to cause steatosis
(e.g. amiodarone, tamoxifen, steroids, valproic acid, metho-
trexate, zidovudine) within the past 3 months or for >6
months in the past 2 years), rapid weight loss and total
parenteral nutrition.
A detailed history and physical examination including
anthropometry was carried out for every patient. Lipid profile,
serum bilirubin, liver enzymes (AST and ALT), TNF-a and hs-
CRP levels were done for all patients. Hs-CRP estimation was
performed by solid phase enzyme linked immunosorbent
assay (ELISA) using UBIMAGIWEL CRP-quantitative AD-401 kit
as per instructions of the manufacturer (supplied with kit);
with reference range for hs-CRP being 0.0e0.8 mg/dl. TNF-a
(pg/ml) levels were determined by use of a commercial ELISA
Kit (R & D Systems). Relevant investigations to exclude other
Table 1 e Metabolic and biochemical parameters in patients with and without NAFLD.
Parameter Total (n ¼ 104) With NAFLD (n ¼ 72) Without NAFLD (n ¼ 32) p-value
Hypertensionb 58 (55.8) 34 (47.2) 24 (75) 0.008
Diabetesb 14 (13.5) 10 (13.9) 4 (12.5) 0.848
Metabolic syndromeb 42 (40.4) 38 (52.8) 4 (12.5) <0.001
Smokingb 54 (51.9) 42 (58.3) 12 (37.5) 0.050
Waist circumference (cm)a 86.99 ± 11.6 88.5 ± 11.3 83.63 ± 11.7 0.052
No. with increased waist circumferenceb 52 (50) 44 (84.6) 8 (15.4) 0.001
Abdominal circumference (cm)a 91.81 ± 12.2 93.7 ± 11.5 87.6 ± 12.8 0.026
Hip circumference (cm)a 91.13 ± 8.6 92.6 ± 11.5 87.7 ± 12.8 0.018
BMI (kg/m2)a 23.01 ± 3.9 23.7 ± 3.8 21.4 ± 3.5 0.003
Obesityb 34 (32.7%) 28 (38.9%) 6 (18.8%) 0.043
Serum triglyceride level (mg/dL)a 151.50 ± 63.4 161.9 ± 67.9 128 ± 44.2 0.003
No. with Impaired triglyceride levelb 50 (48.1) 42 (58.3) 8 (25) 0.002
HDL cholesterol (mg/dL)a 38.19 ± 9.6 38 ± 9.7 38.7 ± 9.3 0.723
No. with Impaired HDL levelsb 60 (57.7) 48 (66.7) 12 (37.5) 0.005
AST levels (U/L)a 21.17 ± 10.8 22.4 ± 11.7 18.2 ± 7.9 0.034
ALT levels (U/L)a 20.29 ± 11.9 21 ± 13.2 18.6 ± 8.4 0.268
TNFa (pg/ml)a 113.39 ± 16.56 118.59 ± 15.83 101.68 ± 11.53 <0.001
hs-CRP (mg/L)a 5.08 ± 1.46 5.51 ± 1.39 4.11 ± 1.09 <0.001
a Values are expressed as mean ± SD.
b Values are expressed as number (%).
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were also done. USG abdomen was performed with the
Sonoline 500model (Siemens) using 3.5MHz real time scanner
and grading was done as follows:
 Grade I: a slight diffuse increase in fine echoes in the he-
patic parenchyma with normal visualization of the dia-
phragm and intrahepatic vessel borders.
 Grade II: a moderate diffuse increase in fine echoes with
slightly impaired visualization of the intrahepatic vessels
and diaphragm.
 Grade III: a marked increase in fine echoes with poor or no
visualization of intrahepatic vessel borders, diaphragm
and posterior portion of the right lobe of the liver.
All statistical data were analyzed by using SPSS software
version 15.0. Statistical package for windows (Chicago. Inc.).
Continuous variables were expressed as mean ± standard
deviation and qualitative data was expressed as percentage.
Depending on normality distribution, unpaired t test for in-
dependent samples was used for comparing continuous var-
iables between two groups. Linear relationship between
variables was analyzed using Pearson's correlation coefficient
and significance of ‘r’ was tested. A Stepwise multivariate
regression analysis was used to study the determinants of
NAFLD. All p values were two tailed and values of p < 0.05 was
considered statistically significant. All confidence intervals
were calculated at 95% level.3. Results
The study group comprised of 84 (80.8%) males and 20 (19.2%)
females. 20 (19.2%) patients had hypertensive heart disease
and the remaining 84 patients (80.8%) had ischemic heart
disease (IHD) either alone or in combination with essential
hypertension.NAFLD was identified in 69.2% (72/104) patients on the
basis of USG. Of these 50% (36/72) had grade 1 NAFLD and the
rest (36/72) had grade 2 NAFLD, there was no patient with
grade 3 NAFLD. Most patients with NAFLD (63.8%), were in the
age group of 40e60 years. Overall, themean age of the patients
was 54.73 ± 11.7 years. In the NAFLD group, it was 53.8 ± 11.7
years and in thosewithout NAFLD, it was 56.8± 11.4 years. Age
did not have any significant association with NAFLD
(p ¼ 0.223).
As shown in Table 1metabolic syndrome and its individual
components were significantly more common in patients of
CVDwith NAFLD. Hypertension, dyslipidemia, central obesity,
BMI, were all more common in patients with NAFLD. Also
patients with NAFLD had higher levels of AST. Both the
markers of inflammation measured in this study (hs-CRP and
TNFa) were significantly higher in patients with NAFLD.
The levels of inflammatory markers were also associated
with the severity of NAFLD. As shown in Fig. 1, patients with
grade II NAFLD had significantly higher levels of TNF-a.
Similarly patients with Grade II NAFLD also had significantly
higher levels of hs-CRP as compared with grade I NAFLD
(Fig. 2). Risk factors for occurrence NAFLD amongst patients
with cardiovascular diseasewere assessedwith binary logistic
regression; which showed that only BMI, serum triglyceride
levels, waist circumference and hypertension were indepen-
dently associated with the presence of NAFLD (Table 2). Age,
sex, waist, abdominal and hip circumference, HDL and LDL
levels, diabetes mellitus, smoking history and ALT and AST
levels were not found to be significantly related to NAFLD.4. Discussion
With increasing recognition of the relationship of NAFLDwith
the metabolic syndrome, interest has been stimulated in the
possible role of NAFLD in the development of atherosclerosis.
It has been observed that patients with NAFLD have a greater
Fig. 2 e Levels of hs-CRP in patient groups with and
without NAFLD.
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of NAFLD (69.2%) in patients with CVD found in our study
further supports the association of NAFLD with cardiovascu-
lar diseases. We also found that metabolic syndrome and its
components were significantly more common in patients of
CVD who had NAFLD. Also, BMI, serum triglyceride levels,
waist circumference and hypertension were found to be in-
dependent predictor of presence of NAFLD (Table 2). The as-
sociation of NAFLD and metabolic syndrome has been
established previously as well.3,4
Recent studies have shown that NAFLD and its necroin-
flammatory form NASH are also associated with increased
plasma inflammatory biomarker.14,20,24 Several inflammatory
processes, mainly associated with tumor necrosis factor a
(TNF-a), have been associated with NAFLD.16 This inflamma-
tory pathway is also shared by cardiovascular disease.17,18
High-sensitivity C-reactive protein (hs-CRP) which has
important clinical and prognostic implications in cardiovas-
cular disease; however, has not been well studied in NAFLD.25
High-sensitivity C-reactive protein (hs-CRP) assay is a
marker of inflammation and is recommended for use as a part
of coronary risk assessment in adults with intermediate car-
diovascular risk. In our study, the hs-CRP levels were signifi-
cantly higher in the NAFLD group compared to cases without
NAFLD. The levels were also higher in Grade II versus Grade I
NAFLD patients (p < 0.001). Targher et al also found that
plasma level of hs-CRP in patients with biopsy-proven NASH
was significantly higher than those in non-obese healthy
subjects, and in overweight non-steatotic patients.26 Another
study showed that NAFLD patients had an increased con-
centration of ultrasensitive CRP, independently of other
metabolic factors.27
Tumor necrosis factors (TNF-a) has been reported to be
associated with insulin resistance and induce inflammatory
cytokines formation. In our study, the higher TNF-a levels
were significantly associated with NAFLD and increasing
severity of fatty liver (p < 0.001). In another study from China,Fig. 1 e Levels of TNF a in patient groups with and without
NAFLD.patients with NAFLD complicated with more risk factors of
metabolic syndrome, had progressive elevation in plasma
TNF-a levels (p¼ 0.05).28 Since TNF-a is involved in the genesis
and development of NAFLD and metabolic syndrome, it may
be one of the inflammatory factors that links these two dis-
eases. Inhibition of TNF-a activitymay be a potential approach
to treat more severe forms of NAFLD.
The increased levels of inflammatory biomarkers in pa-
tients with NAFLDmay have some role in the pathogenesis of
CVD in those patients or it might just be a marker of severe
systemic inflammation responsible for the causation of both
CVD and NAFLD from independent risk factors.
The limitations of our study were: Firstly, its cross-
sectional design precludes any causal and temporal in-
ferences about the relationships between the presence of
NAFLD and cardiovascular disease. Secondly, the diagnosis of
NAFLD was made by ultrasound imaging and exclusion of
other causes of chronic liver disease, but was not confirmed by
liver biopsy.5. Conclusions
Our study highlights the high prevalence of NAFLD in patients
with established cardiovascular diseases. NAFLD was alsoTable 2 e Odds ratio and 95% Confidence intervals (CI) for
NAFLD using binary logistic regression analysis.
Covariates Odds ratio 95% CI p-
value
BMI (kg/m2) 2.015 1.341e3.026 0.001
Serum triglyceride level (mg/dL) 1.017 1.006e1.029 0.002
Waist circumference (cm) 0.868 0.781e0.965 0.009
Hypertension (n) 0.030 0.005e0.169 0.000
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 5 7 4e5 7 9578found to be significantly associated with manifestations of
metabolic syndrome and markers of inflammation (hs-CRP
and TNF-a). This aggregation of metabo-inflammatory
markers in patints with NAFLD and CVD highlights the com-
mon risk factors and shared pathophysiological pathways of
both the diseases. Further long term prospective studies can
shed more light on the exact role of NAFLD in the patho-
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